• Mucociliary ClearanceCompleted with Results

  Pulmozyme in 3-5 Year Old Children with CF , protocol number Genentech Z4240g

  This study looked at the effect of Pulmozyme on preschool aged (3-5 year old) children.

  • Age:

    3 Years to 5 Years

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    No FEV1 Limit

  • Number of Visits:

    3

  • Length of Participation:

    32 days

• OtherCompleted with Results

  SIMPLIFY: Study to evaluate stopping inhaled hypertonic saline or dornase alfa in people with CF who are taking Trikafta® , protocol number SIMPLIFY-IP-19

  This study evaluated the effects and safety of stopping inhaled hypertonic saline or dornase alfa (Pulmozyme®) in teens and adults with CF who are also taking the triple-combination modulator, elexacaftor/tezacaftor/ivacaftor (Trikafta®). 

  • Age:

    12 Years and Older

  • Mutation(s):

    No Mutation Requirement

  • FEV1% Predicted:

    60% or greater

  • Number of Visits:

    4

  • Length of Participation:

    10 weeks

Studies in this tool are multi-center studies facilitated by the Cystic Fibrosis Therapeutics Development Network. For a complete list of cystic fibrosis related studies, visit www.clinicaltrials.gov.